Johnson & Johnson Leads Global Pharma Sales at $55.8 Billion; Merck Tops R&D Spending

The global pharmaceutical industry and worldwide drug market reached a value of nearly $1.7 trillion, driven by treatments for chronic, oncological, and metabolic diseases, according to the "Top pharmaceutical drugs" report published in December 2025. Johnson & Johnson led the global ranking in 2024 with prescription sales of approximately $55.8 billion.

The U.S.-based company remains at the top thanks to its diversified medicine portfolio, particularly in oncology, immunology, and hematology, with key brands such as Darzalex and Stelara. Johnson & Johnson is among the companies that invest the most in research, allocating more than $17 billion to R&D, reflecting its long-term strategy within the pharmaceutical industry.

Leadership is concentrated among a small group of giants. AbbVie recorded prescription sales of approximately $54.5 billion with R&D spending of approximately $8 billion. Merck & Co. achieved prescription sales of approximately $54.3 billion and led research investment at approximately $17.8 billion. Roche reported prescription sales of approximately $52.4 billion with R&D spending of approximately $14.8 billion. Pfizer recorded prescription sales of approximately $51.9 billion with R&D investment of approximately $10.8 billion.

These companies account for a significant share of the global drug business, particularly in therapeutic areas linked to highly prevalent diseases such as cancer, diabetes, and autoimmune conditions.

The global top 10 by prescription sales is completed by AstraZeneca, Novartis, Bristol Myers Squibb, Sanofi, and Novo Nordisk. Novo Nordisk has gained global relevance thanks to the success of diabetes and obesity drugs such as Ozempic and Wegovy, positioning itself as one of the most influential brands today within the pharmaceutical industry.

When the focus shifts to research spending, the ranking changes slightly. Merck & Co. and Johnson & Johnson compete for leadership in investment, with figures exceeding $17 billion annually in R&D. Other companies that stand out for their scientific commitment include Roche, with strong investment in biotechnology and oncology; AstraZeneca, which allocates more than $12 billion to research, driven by its oncology pipeline; and Novartis, combining high revenues with a strong focus on medical innovation.

This spending is key to developing new medicines, protecting patents, and responding to complex diseases that require next-generation treatments.

The company that sells the most is not always the one that invests the most in research and development. Some pharmaceutical companies maintain high revenues thanks to established drugs, while others bet more heavily on the development of new therapies. This gap is explained by several factors: drug life cycles and proximity to patent expiration, growth strategies based on acquisitions, and priority in therapeutic areas with higher economic returns. In all cases, research investment remains a strategic pillar to sustain competitiveness in the face of new diseases and global health challenges.